Objectives: ... Here, we reported a case of lung adenocarcinoma harboring a novel S1 RNA binding domain 1 (SRBD1)–ALK fusion which the breakpoints was (S6,A20). To our knowledge, this case is the first report showed clinical evidence of SRBD1-ALK fusion responding to crizotinib. Conclusion: To our knowledge, our case is the first case of SRBD1-ALK fusion with excellent response to crizotinib. This case merits further follow-up and provides valuable information on the response to crizotinib of NSCLC patients with SRBD1-ALK fusion. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2020.04.031
Authors: Yao, Chen, Xiaochen Zhang, Qi Jiang, Bo Wang, Yina Wang, Yan Junrong
